Contact Us

HLA-DRB (MHC II) Antibody [Bra30]

Additional information

Catalog Number: 3123-MSM4
Reactivity:

, , , , ,

Gene:

Host:

In Stock

Trial Size Available

Carrier-Free Available

download data sheet
In Stock
Catalog Number Formulation Size Price
3123-MSM4-P0
Purified Ab with BSA and Azide at 200ug/ml
20ug
$259.00
3123-MSM4-P1
Purified Ab with BSA and Azide at 200ug/ml
100ug
$559.00
3123-MSM4-P1ABX
Purified Ab WITHOUT BSA and Azide at 1.0mg/ml
100ug
$559.00
Flat Rate Domestic: $95 | Orders outside the US - Contact Us for Order Information | Ships next business day
HLA-DRB Antibody in SDS-PAGE

HLA-DRB Antibody in SDS-PAGE

SDS-PAGE Analysis of Purified HLA-DRB Mouse Monoclonal Antibody (BRA30).Confirmation of Purity and Integrity of Antibody.

  • Flow
  • IF
  • Documents
  • Applications & Dilutions
  • Product Properties
  • other information

Documents

Document Name
Datasheet Download Here
Material Safety Data Sheet Download Here

Applications & Dilutions

Applications Tested Dilutions Protocol
Flow Cytometry (Flow) 1-2ug/million cells Flow Cytometry Protocol
Immunofluorescence (IF) 1-3ug/ml

Product Properties

Antibody Type
Mouse Monoclonals
Host
Mouse
Applications
Flow Cytometry, Immunofluorescence
Species Reactivity
Baboon, Chimpanzee, Dog, Human, Monkey, Squirrel
Clone
Bra30
Isotype
IgG2a
Light Chain
Kappa
Cellular Localization
Autolysosome membrane, Cell membrane, Endoplasmic reticulum membrane, Late endosome membrane, Lysosome membrane
Gene Name
HLA-DRB1
Positive Control
Daudi or HuT78 cells. Tonsil or lymph node., Ramos
Immunogen
Human REH cells (non-T, non-B leukemia cell line)
Storage & Stability
Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous. No MSDS required.
Supplied as
200ug/ml of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/ml.
Limitations
This antibody is available for research use only and is not approved for use in diagnosis.

Related Antibodies

SDS-PAGE Analysis of Purified P-Cadherin Mouse Monoclonal Antibody (6A9). Confirmation of Integrity and Purity of Antibody.
0
  • Flow
  • IF
  • WB

P-Cadherin (CDH3) Antibody

Additional information

Catalog Number: 1001-MSM2
Reactivity:

Gene:

Host:

Formalin-fixed, paraffin-embedded human Kidney stained with Occludin Mouse Monoclonal Antibody (OCLN/2183).
4
  • IHC
  • WB

Occludin (OCLN) (Tight Junctions Marker) Antibody

Additional information

Catalog Number: 100506658-MSM3
Reactivity:

Gene:

Host:

Formalin-fixed, paraffin-embedded human kidney stained with MICA Mouse Recombinant Monoclonal Antibody (MICA/4442). HIER: Tris/EDTA, pH9.0, 45min. 2°C: HRP-polymer, 30min. DAB, 5min.
5
  • IHC
  • WB

MICA Antibody

Additional information

Catalog Number: 100507436-MSM2
Reactivity:

, , , ,

Gene:

Host:

Formalin-fixed, paraffin-embedded human Renal Cell Carcinoma stained with Cadherin 16 Mouse Monoclonal Antibody (CDH16/2448).
3
  • ELISA
  • IHC

Ksp-Cadherin / CDH16 (Renal Cell Marker) Antibody

Additional information

Catalog Number: 1014-MSM6
Reactivity:

Gene:

Host:

Formalin-fixed, paraffin-embedded human Renal Cell Carcinoma stained with KSP-Cadherin Mouse Monoclonal Antibody (CDH16/1071).
7
  • ELISA
  • Flow
  • IHC
  • WB

Ksp-Cadherin (Kidney-Specific Cadherin) / CDH16 Antibody

Additional information

Catalog Number: 1014-MSM1
Reactivity:

, , , ,

Gene:

Host:

Flow cytometric analysis of PFA-fixed HeLa cells. HDAC6 Mouse Monoclonal Antibody (PCRP-HDAC6-1A4) followed by goat anti-mouse IgG-CF488 (blue), unstained cells (red).
3
  • Flow
  • IF

HDAC6 Antibody

Additional information

Catalog Number: 10013-MSM1
Reactivity:

Gene:

Host:

SDS-PAGE Analysis of Purified CDH16 Rabbit Recombinant Monoclonal Antibody (CDH16/7027R). Confirmation of Purity and Integrity of Antibody.
5
  • IHC
  • WB

Recombinant Ksp-Cadherin (Kidney-Specific Cadherin) / CDH16 Antibody

Additional information

Catalog Number: 1014-RBM10
Gene:

Host:

Reactivity:

Formalin-fixed, paraffin-embedded human heart stained with N-Cadherin Recombinant Rabbit Monoclonal Antibody (CDH2/3874R).
3
  • IHC
  • WB

Recombinant N-Cadherin / Cadherin-2 / CD325 (NCAD) Antibody

Additional information

Catalog Number: 1000-RBM5
Gene:

Host:

Reactivity:

, , ,

VIEW ALL ANTIBODIES

Other Information

Functions
  • A beta chain of antigen-presenting major histocompatibility complex class II (MHCII) molecule. In complex with the alpha chain HLA-DRA, displays antigenic peptides on professional antigen presenting cells (APCs) for recognition by alpha-beta T cell receptor (TCR) on HLA-DRB1-restricted CD4-positive T cells. This guides antigen-specific T-helper effector functions, both antibody-mediated immune response and macrophage activation, to ultimately eliminate the infectious agents and transformed cells (PubMed:29884618, PubMed:22327072, PubMed:27591323, PubMed:8642306, PubMed:15265931, PubMed:31495665, PubMed:16148104). Typically presents extracellular peptide antigens of 10 to 30 amino acids that arise from proteolysis of endocytosed antigens in lysosomes (PubMed:8145819). In the tumor microenvironment, presents antigenic peptides that are primarily generated in tumor-resident APCs likely via phagocytosis of apoptotic tumor cells or macropinocytosis of secreted tumor proteins (PubMed:31495665). Presents peptides derived from intracellular proteins that are trapped in autolysosomes after macroautophagy, a mechanism especially relevant for T cell selection in the thymus and central immune tolerance (PubMed:17182262, PubMed:23783831). The selection of the immunodominant epitopes follows two processing modes: 'bind first, cut/trim later' for pathogen-derived antigenic peptides and 'cut first, bind later' for autoantigens/self-peptides (PubMed:25413013). The anchor residue at position 1 of the peptide N-terminus, usually a large hydrophobic residue, is essential for high affinity interaction with MHCII molecules (PubMed:8145819).
  • Allele DRB1*01:01: Displays an immunodominant epitope derived from Bacillus anthracis pagA/protective antigen, PA (KLPLYISNPNYKVNVYAVT), to both naive and PA-specific memory CD4-positive T cells (PubMed:22327072). Presents immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load (PubMed:29884618). May present to T-helper 1 cells several HRV-16 epitopes derived from capsid proteins VP1 (PRFSLPFLSIASAYYMFYDG) and VP2 (PHQFINLRSNNSATLIVPYV), contributing to viral clearance (PubMed:27591323). Displays commonly recognized peptides derived from IAV external protein HA (PKYVKQNTLKLAT and SNGNFIAPEYAYKIVK) and from internal proteins M, NP and PB1, with M-derived epitope (GLIYNRMGAVTTEV) being the most immunogenic (PubMed:8145819, PubMed:9075930, PubMed:25413013, PubMed:32668259). Presents a self-peptide derived from COL4A3 (GWISLWKGFSF) to TCR (TRAV14 biased) on CD4-positive, FOXP3-positive regulatory T cells and mediates immune tolerance to self (PubMed:28467828). May present peptides derived from oncofetal trophoblast glycoprotein TPBG 5T4, known to be recognized by both T-helper 1 and regulatory T cells (PubMed:31619516). Displays with low affinity a self-peptide derived from MBP (VHFFKNIVTPRTP) (PubMed:9075930).
  • Allele DRB1*03:01: May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (NEKQPSDDNWLNFDGTLLGN), contributing to viral clearance (PubMed:27591323). Displays self-peptides derived from retinal SAG (NRERRGIALDGKIKHE) and thyroid TG (LSSVVVDPSIRHFDV) (PubMed:25413013). Presents viral epitopes derived from HHV-6B gH/U48 and U85 antigens to polyfunctional CD4-positive T cells with cytotoxic activity implicated in control of HHV-6B infection (PubMed:31020640). Presents several immunogenic epitopes derived from C. tetani neurotoxin tetX, playing a role in immune recognition and long-term protection (PubMed:19830726).
  • Allele DRB1*04:01: Presents an immunodominant bacterial epitope derived from M. tuberculosis esxB/culture filtrate antigen CFP-10 (EISTNIRQAGVQYSR), eliciting CD4-positive T cell effector functions such as IFNG production and cytotoxic activity (PubMed:15265931). May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (NEKQPSDDNWLNFDGTLLGN), contributing to viral clearance (PubMed:27591323). Presents tumor epitopes derived from melanoma-associated TYR antigen (QNILLSNAPLGPQFP and DYSYLQDSDPDSFQD), triggering CD4-positive T cell effector functions such as GMCSF production (PubMed:8642306). Displays preferentially citrullinated self-peptides derived from VIM (GVYATR/citSSAVR and SAVRAR/citSSVPGVR) and ACAN (VVLLVATEGR/ CitVRVNSAYQDK) (PubMed:24190431). Displays self-peptides derived from COL2A1 (PubMed:9354468).
  • Allele DRB1*04:02: Displays native or citrullinated self-peptides derived from VIM.
  • Allele DRB1*04:04: May present to T-helper 1 cells several HRV-16 epitopes derived from capsid proteins VP1 (HIVMQYMYVPPGAPIPTTRN) and VP2 (RGDSTITSQDVANAVVGYGV), contributing to viral clearance (PubMed:27591323). Displays preferentially citrullinated self-peptides derived from VIM (SAVRAR/citSSVPGVR) (PubMed:24190431).
  • Allele DRB1*04:05: May present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (KRYFKLSHLQMHSRKH), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies.
  • Allele DRB1*05:01: Presents an immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load.
  • Allele DRB1*07:01: Upon EBV infection, presents latent antigen EBNA2 peptide (PRSPTVFYNIPPMPLPPSQL) to CD4-positive T cells, driving oligoclonal expansion and selection of a dominant virus-specific memory T cell subset with cytotoxic potential to directly eliminate virus-infected B cells (PubMed:31308093). May present to T-helper 1 cells several HRV-16 epitopes derived from capsid proteins VP1 (PRFSLPFLSIASAYYMFYDG) and VP2 (VPYVNAVPMDSMVRHNNWSL), contributing to viral clearance (PubMed:27591323). In the context of tumor immunesurveillance, may present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (MTEYKLVVVGAVGVGKSALTIQLI), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies (PubMed:22929521). In metastatic epithelial tumors, presents to intratumoral CD4-positive T cells a KRAS neoantigen (MTEYKLVVVGAVGVGKSALTIQLI) carrying G12V hotspot driver mutation and may mediate tumor regression (PubMed:30282837).
  • Allele DRB1*11:01: Displays an immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load (PubMed:29884618). May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (SDRIIQITRGDSTITSQDVA), contributing to viral clearance (PubMed:27591323). Presents several immunogenic epitopes derived from C. tetani neurotoxin tetX, playing a role in immune recognition and longterm protection (PubMed:19830726). In the context of tumor immunesurveillance, may present tumor-derived neoantigens to CD4-positive T cells and trigger anti-tumor helper functions (PubMed:31495665).
  • Allele DRB1*13:01: Presents viral epitopes derived from HHV-6B antigens to polyfunctional CD4-positive T cells implicated in control of HHV-6B infection.
  • Allele DRB1*15:01: May present to T-helper 1 cells an HRV-16 epitope derived from capsid protein VP2 (SNNSATLIVPYVNAVPMDSM), contributing to viral clearance (PubMed:27591323). Displays a self-peptide derived from MBP (ENPVVHFFKNIVTPR) (PubMed:9782128, PubMed:25413013). May present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (KRYFKLSHLQMHSRKH), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies.
  • Allele DRB1*15:02: Displays an immunodominant HIV-1 gag peptide (FRDYVDRFYKTLRAEQASQE) on infected dendritic cells for recognition by TRAV24-TRBV2 TCR on CD4-positive T cells and controls viral load (PubMed:29884618). May present to T-helper 1 cells an immunogenic epitope derived from tumor-associated antigen WT1 (KRYFKLSHLQMHSRKH), likely providing for effective antitumor immunity in a wide range of solid and hematological malignancies (PubMed:19120973).
  • (Microbial infection) Acts as a receptor for Epstein-Barr virus on lymphocytes.
Key References
  • Cresswell, P., 1996. Cell 84. 505-507
  • Barclay, A.N., et al., eds. 1997. The Leucocyte Antigen Facts Book. Academic Press. London
  • Seddon, B., and Mason, D., 1996. Int. Immunol. 8. 1185-1193
PubMed Links
Warranty
There are no warranties, expressed or implied, which extend beyond this description. Company is not liable for any personal injury or economic loss resulting from this product.
Entrez Gene ID
3123
SwissProt
P01911
Chromosome Location
6p21.3
Mol. Weight of Antigen
~28kDa (beta chain)
Alternate Names
HLA class II histocompatibility antigen, DRB1 beta chain, Human leukocyte antigen DRB1, HLA class II histocompatibility antigen DR beta 3 chain; HLADR3B; Major histocompatibility complex, class II DR beta 3

Summary

This MAb reacts with the HLA-DRB3 antigen, a member of MHC class II molecules.It does not cross react with HLA-DP and HLA-DQ. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36kDa alpha (heavy) chain and a 28kDa beta (light) chain. It is expressed on B-cells, activated T-cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4+ T cells. HLA-DR antigens also occur on a variety of epithelial cells and their corresponding neoplastic counterparts.

Worry-Free Guarantee

Should a NeoBiotechnologies antibody not meet the experimental expectations outlined on our website or datasheet, please contact our Technical Support. We unconditionally guarantee our product.

Learn More

Need Technical Help?

Our team of scientists are ready to help you with expert recommendations or technical assistance related to applications or product use.

CONTACT US

Follow Us on LinkedIn

NeoBiotechnologies develops and manufactures highly specific, validated monoclonal antibodies for cancer research and diagnostics.

Phone

Whatsapp

Quick Links

Information

© 2026 NeoBiotechnologies.  All Rights Reserved.

Terms and Conditions Privacy Policy
Contact Us